A detailed history of Price T Rowe Associates Inc transactions in Immunovant, Inc. stock. As of the latest transaction made, Price T Rowe Associates Inc holds 1,361,649 shares of IMVT stock, worth $37.5 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
1,361,649
Previous 1,862,043 26.87%
Holding current value
$37.5 Million
Previous $60.2 Million 40.25%
% of portfolio
0.0%
Previous 0.01%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

SELL
$25.1 - $31.61 $12.6 Million - $15.8 Million
-500,394 Reduced 26.87%
1,361,649 $35.9 Million
Q1 2024

May 15, 2024

BUY
$30.27 - $43.79 $7.85 Million - $11.4 Million
259,481 Added 16.19%
1,862,043 $60.2 Million
Q4 2023

Feb 14, 2024

BUY
$31.31 - $44.19 $27.3 Million - $38.6 Million
872,520 Added 119.52%
1,602,562 $67.5 Million
Q3 2023

Nov 14, 2023

BUY
$18.55 - $39.96 $13.2 Million - $28.4 Million
710,514 Added 3638.44%
730,042 $28 Million
Q2 2023

Aug 14, 2023

SELL
$14.2 - $23.75 $6.02 Million - $10.1 Million
-423,676 Reduced 95.59%
19,528 $371,000
Q1 2023

May 15, 2023

BUY
$15.27 - $19.72 $2.55 Million - $3.3 Million
167,205 Added 60.58%
443,204 $6.88 Million
Q4 2022

Feb 14, 2023

BUY
$6.59 - $17.75 $1.82 Million - $4.9 Million
275,999 New
275,999 $4.9 Million
Q4 2021

Feb 14, 2022

SELL
$7.33 - $9.32 $166,244 - $211,377
-22,680 Closed
0 $0
Q3 2021

Nov 15, 2021

BUY
$7.01 - $11.37 $35,589 - $57,725
5,077 Added 28.84%
22,680 $197,000
Q2 2021

Aug 16, 2021

BUY
$9.4 - $16.85 $3,243 - $5,813
345 Added 2.0%
17,603 $186,000
Q1 2021

May 17, 2021

SELL
$13.08 - $49.6 $3.57 Million - $13.5 Million
-272,730 Reduced 94.05%
17,258 $277,000
Q4 2020

Feb 16, 2021

BUY
$36.36 - $52.71 $10.5 Million - $15.3 Million
289,988 New
289,988 $13.4 Million

Others Institutions Holding IMVT

About Immunovant, Inc.


  • Ticker IMVT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 129,077,000
  • Market Cap $3.55B
  • Description
  • Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in Phase IIa clinical trials for the treatment of mya...
More about IMVT
Track This Portfolio

Track Price T Rowe Associates Inc Portfolio

Follow Price T Rowe Associates Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Price T Rowe Associates Inc , based on Form 13F filings with the SEC.

News

Stay updated on Price T Rowe Associates Inc with notifications on news.